Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has entered into a three-year exclusive sales and marketing agreement with Eurobio for the distribution of the OncAlert Oral Cancer Risk Assessment System in France, Algeria, Morocco and Tunisia. The OncAlert Oral Cancer Risk Assessment System includes theOncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test (OncAlert POC Test) and the OncAlert Oral Cancer CD44 + Total Protein Lab Test (OncAlert LAB Assay).
Under the terms of the agreement, Eurobio will exclusively market and sell the OncAlert POC Test and OncAlert LAB Assay to the oral oncology markets in France, Algeria, Morocco and Tunisia pursuant to the CE Mark registration approvals of the products, which are expected by Q3 2015. Financial terms were not disclosed.
Headquartered in Les Ulis, France, Eurobio is a leading developer, manufacturer and marketer of high-quality, innovative in-vitro diagnostic products for biotechnology, research and pharmaceutical laboratories.
“We are pleased to announce the agreement with Eurobio for the sale of our OncAlert System in France, Algeria, Morocco and Tunisia,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences, Inc. “Our distribution partners will be critical to our efforts to bring our oral cancer risk assessment system to the hundreds of thousands who suffer from oral cancer each year. Through our partnership with Eurobio, our goal is to provide innovative, effective and cost-effective products that will result in earlier detection and intervention for patients.”
Based on 2012 incidence rate estimates by International Agency for Research on Cancer, there were more than 18,900 cases of head and neck cancer in France in 2012. Additionally, according to the World Health Organization and the HPV Information Centre, more than 38 million more people in France are at risk for oral cancer due to tobacco use, heavy drinking, or exposure to the HPV virus – key risk factors for the disease.
“We are excited to partner with Vigilant Biosciences to bring this important test to patients in France and North Africa,” said Jean-Michel Carle, CEO of Eurobio. “When healthcare professionals are armed with this system to quickly and accurately assess the risk of oral cancer, before it progresses to late stage, lives can be saved.”
About the OncAlert Oral Cancer Risk Assessment System
Vigilant’s initial product, the OncAlert Oral Cancer Risk Assessment System, includes the OncAlert Oral Cancer Rapid Point-of-Care Risk Assessment Test and the OncAlert Oral Cancer CD44 + Total Protein Lab Test. Both products in the OncAlert System are based on patented technology that detects specific protein markers known to indicate an elevated risk for oral cancer, even prior to the observation of visual or physical symptoms. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The test can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume alcohol, and people with HPV.) Both products that comprise the OncAlert Oral Cancer Risk Assessment System are currently under the CE Mark registration approval process and expected for release by Q3 2015.
About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.